Log in to search using one of your social media accounts:

 

Library Shelfie Day
The New York Public Library launched ‘Library Shelfie Day’, a social media event, a few years ago as a way to promote libraries and demonstrate a love of reading. The idea worked well with Instagram and was an international hit with over 1200 posts. Why did people like it so much? A number of factors contributed to this phenomenon. It definitely resonated with what people cared about, their passion for reading. Wonderful books include both the courageous and inspiring stories of individuals as well as reveal the health barriers members of our society must face. The PNR staff loves to read and here are a few of...
Source: Dragonfly - January 23, 2018 Category: Databases & Libraries Authors: Carolyn Martin Tags: Health Literacy/Consumer Health Public Libraries reading social media Source Type: news

Individual versus group cognitive-behavioral therapy for partner-violent men: a preliminary randomized trial - Murphy CM, Eckhardt CI, Clifford JM, Lamotte AD, Meis LA.
A randomized clinical trial tested the hypothesis that a flexible, case formulation-based, individual treatment approach integrating motivational interviewing strategies with cognitive-behavioral therapy (ICBT) is more efficacious than a standardized group... (Source: SafetyLit)
Source: SafetyLit - January 23, 2018 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news

A brief exposure-based treatment vs cognitive processing therapy for posttraumatic stress disorder: a randomized noninferiority clinical trial - Sloan DM, Marx BP, Lee DJ, Resick PA.
IMPORTANCE: Written exposure therapy (WET), a 5-session intervention, has been shown to efficaciously treat posttraumatic stress disorder (PTSD). However, this treatment has not yet been directly compared with a first-line PTSD treatment such as cognitive ... (Source: SafetyLit)
Source: SafetyLit - January 23, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

TriNetX buffs Sanofi's digital trials and other digital health deals
Sanofi has found yet another partner to help digitize its clinical trial processes. In a statement, TriNetX announced that it will be assisting the pharmaceutical company by using patient EHRs to optimize recruitment, streamline trial investigators ’ workflows, and otherwise impact the design of investigational drug trials. Sanofi has made similar arrangements to bolster its clinical trials with Science 37 and Evidation in March and July of last year, respectively. (Source: mobihealthnews)
Source: mobihealthnews - January 22, 2018 Category: Information Technology Source Type: news

Updates on NCCIH Clinical Trials Among Talks To Be Streamed at Feb. 9 Advisory Council Meeting
On Friday, February 9, the  National Advisory Council for Complementary and Integrative Health (NACCIH) will hold its second meeting of Fiscal Year 2018. NCCIH grantees, potential applicants, and others may find it useful to hear updates on the Center’s activities, policies, and funding priorities. We will provide a livestream of the meeting’s open session via NIH Videocast from 10:00 a.m. to 3:05 p.m. ET. (Source: NCCAM Featured Content)
Source: NCCAM Featured Content - January 19, 2018 Category: Complementary Medicine Authors: Partap Khalsa, D.C., Ph.D. Source Type: news

Laminate Medical launches study of VasQ hemodialysis fistula device
Laminate Medical Technologies said today it launched a pivotal, FDA-cleared trial of its VasQ implanted blood vessel device designed for patients requiring arteriovenous fistulas as vascular access for hemodialysis. The Israel-based company’s VasQ device is designed to aid kidney failure patients in need of dialysis by providing external support to reduce fistula failure. The device regulates flow by constraining and shaping the fistula and reinforces and shields the perianastomotic vein against high pressure, wall tension and flow levels, the company said. The first procedures in the trial were recently perform...
Source: Mass Device - January 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Vascular Laminate Medical Technologies Source Type: news

What's Hot at ISC 2018? What's Hot at ISC 2018?
The American Heart Association/American Stroke Association's International Stroke Conference will deliver a host of exciting clinical trial results, as well as new guidelines for acute ischemic stroke.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 19, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

HHS releases new rule on health workers ’ religious, moral objections
Citing President Trump's “pro-life mission,” the Health and Human Services Department announced actions on Friday that are designed to roll back key health-care policies of the Obama administration. Roger Severino, director for the HHS Office of Civil Rights, said a proposed rule on “conscience rights” will further protect health-care workers who think they are being punished or discriminated against because […]Related:New HHS civil rights division charged with protecting health-care workers with moral objectionsTeens are daring each other to eat Tide pods. We don&rsq...
Source: Washington Post: To Your Health - January 19, 2018 Category: Consumer Health News Source Type: news

Why this East Bay drug maker's stock price nearly doubled last year
A new wrinkle to an old treatment helped an East Bay company nearly double its stock price as it moves toward a regulatory decision on its drug for removing "frown lines" between the eyebrows. While the long-term prospects of Revance Therapeutics Inc. (NASDAQ: RVNC) may rest more with the billion-dollar potential of its drug as a longer-lasting alternative to Botox for erasing facial wrinkles, the company is lining up clinical trials testing its drug as a therapeutic against neck spasms , a common… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 19, 2018 Category: American Health Authors: Ron Leuty Source Type: news

Why this East Bay drug maker's stock price nearly doubled last year
A new wrinkle to an old treatment helped an East Bay company nearly double its stock price as it moves toward a regulatory decision on its drug for removing "frown lines" between the eyebrows. While the long-term prospects of Revance Therapeutics Inc. (NASDAQ: RVNC) may rest more with the billion-dollar potential of its drug as a longer-lasting alternative to Botox for erasing facial wrinkles, the company is lining up clinical trials testing its drug as a therapeutic against neck spasms , a common… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 19, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

The flu vaccine could get a much-needed boost
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014 –15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help lower that figure for future flu seasons.The scientists used leading-edge genomics to identify and eliminate the virus ’s defense mechanisms, enabling them to develop a vaccine “candidate” — meaning that it must still undergo evaluation and approval by the FDA — that in animals has been proven to be safe and highly effective against influenza.In the study, which was pu...
Source: UCLA Newsroom: Health Sciences - January 19, 2018 Category: Universities & Medical Training Source Type: news

3rd Annual Clinical Trial Collaborations Event Comes to Boston in...
Led by Co-Chairs Ken Getz, Director of Sponsored Research Programs, Tufts CSDD, and Murray Abramson, MD, VP Global Clinical Operations, Biogen, the...(PRWeb January 19, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15105338.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 19, 2018 Category: Pharmaceuticals Source Type: news

Changes in Bone Markers Predict Fracture Reduction With Anti-resorptive Drug Changes in Bone Markers Predict Fracture Reduction With Anti-resorptive Drug
Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 18, 2018 Category: Orthopaedics Tags: Orthopaedics News Source Type: news

Bluegrass Vascular launches pivotal study for Surfacer vascular access catheter
Bluegrass Vascular Technologies said it enrolled the first patients in a pivotal trial of its Surfacer “inside-out” vascular access catheter. The Surfacer device is designed to provide access to the jugular vein to restore central venous access in hemodialysis patients with blocked neck veins; it won CE Mark approval in the European Union in August 2016; Bluegrass later inked an EU distribution deal with Merit Medical (NSDQ:MMSI) that included an equity stake. Surfacer is designed to be threaded through the femoral vein up to and into blockages in the jugular, which acts as a stabi...
Source: Mass Device - January 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Vascular Bluegrass Vascular Technologies Source Type: news

New HHS civil rights division charged with protecting health-care workers with moral objections
Acting Health and Human Services secretary Eric Hargan on Thursday announced the creation of a new conscience and religious freedom division aimed at protecting doctors, nurses and other health-care workers who decline to participate in care that goes against their moral or religious convictions. Speaking at an event featuring Republican lawmakers and religious leaders, Hargan noted that […]Related:FDA to release more clinical trial information for newly approved drugsCDC postpones session on ‘preparing for the unthinkable’: a nuclear blastFirst treatment approved for breast cancer with BRCA ge...
Source: Washington Post: To Your Health - January 18, 2018 Category: Consumer Health News Source Type: news

With So Many Options, Best CLL Treatment May Be a Clinical Trial With So Many Options, Best CLL Treatment May Be a Clinical Trial
Combination regimens in CLL are already impressive, but new combinations currently being evaluated have strong potential to be even better.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Schistosoma vaccine to enter phase Ib clinical trial
(George Washington University) Researchers at Baylor College of Medicine, in collaboration with a team of researchers at the George Washington University and the Rene Rachou Institute, have received funding from the National Institutes of Health for a Phase Ib clinical trial for a Schistosomiasis vaccine in an endemic area of Brazil. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2018 Category: Infectious Diseases Source Type: news

EDETEK and ClinSmart Announce Partnership
Companies Team Up to Offer Enabling Technologies and Expanded Services to Clinical Trial Sponsors(PRWeb January 18, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15103975.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 18, 2018 Category: Pharmaceuticals Source Type: news

Researchers develop first cortisol treatment specifically designed for infants
EU-funded researchers have developed a treatment tailored for babies and children lacking the stress hormone cortisol. The drug, the first hydrocortisone formulation specifically designed for infants, could become available next year following successful clinical trials. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - January 18, 2018 Category: Research Source Type: news

Previously unpublished information from clinical trial pivotal to FDA approval calls into question effectiveness of pregnancy anti-nausea drug
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - January 17, 2018 Category: Hospital Management Tags: Hospital News Source Type: news

Morning Sickness Drug May Not Work: Study
The drug, Diclegis, failed to meet minimum effectiveness goals in the clinical trial relied upon by the U.S. Food and Drug Administration for its approval in 2013, Canadian researchers reported. (Source: WebMD Health)
Source: WebMD Health - January 17, 2018 Category: Consumer Health News Source Type: news

A family ’ s wrenching goodbye to their 5-year-old touched hearts. Days later, she died.
Braylynn Lawhon's nickname was Princess Bel. Nurses in Florida recently dressed the terminally ill 5-year-old girl in a canary yellow ball gown, “hoping she'll wake up and lose her mind over how she turned into a princess overnight,” her mother wrote Friday on Facebook. “What she doesn't know, though, is that she has ALWAYS been a […]Related:FDA to release more clinical trial information for newly approved drugsTeens are daring each other to eat Tide pods. We don’t need to tell you that’s a bad idea.CDC postpones session on ‘preparing for the unthinkable’: a nuclear bla...
Source: Washington Post: To Your Health - January 17, 2018 Category: Consumer Health News Source Type: news

Writing a monitoring report from beginning to end
John Lehmann, Director of Business Development at IMARC Research Writing great monitoring reports is not just about writing the report. It requires an in-depth knowledge of the job, the study protocol, the site, their practices, the sponsor’s procedures, the monitoring plan, the report template, and of course, the regulations. Attention to visit preparation, clear notetaking during the visit, and prompt, clear report writing pays off in delivering a high-quality document. It is a difficult skill to master, but one that is rewarding, especially when faced with a regulatory inspection. Remember, a well-written monitori...
Source: Mass Device - January 17, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog IMARC Source Type: news

Impact of demographic factors on the antidepressant effect: a patient-level data analysis from depression trials submitted to the Pharmaceuticals and Medical Devices Agency in Japan - Nakabayashi T, Hara A, Minami H.
A substantial and variable placebo response can cause unreliable findings in clinical trials designed to demonstrate the efficacy of antidepressants, and the high rate of failed trials represents a major obstacle in the development of new drugs for major d... (Source: SafetyLit)
Source: SafetyLit - January 17, 2018 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

A school-based neuromuscular training program and sport-related injury incidence: a prospective randomized controlled clinical trial - Foss KDB, Thomas S, Khoury JC, Myer GD, Hewett TE.
CONTEXT:   An estimated 40 million school-aged children (age range = 5-18 years) participate annually in sports in the United States, generating approximately 4 million sport-related injuries and requiring 2.6 million emergency department visits at a cos... (Source: SafetyLit)
Source: SafetyLit - January 17, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Morning Sickness Drug, Diclegis, May Not Work: Study
WEDNESDAY, Jan. 17, 2018 -- The most commonly prescribed medicine for morning sickness may not work, a new report contends. The drug, Diclegis, failed to meet minimum effectiveness goals in the clinical trial relied upon by the U.S. Food and Drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 17, 2018 Category: General Medicine Source Type: news

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages R01 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. (Source: HSR Information Central)
Source: HSR Information Central - January 17, 2018 Category: International Medicine & Public Health Source Type: news

No adverse health impacts from long term vaping -- Study
(Aspect Consulting) A new peer-reviewed clinical trial to be published in the February edition of Regulatory Toxicology and Pharmacology shows that regular use of e-cigarettes does not have any negative health impact on smokers. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 17, 2018 Category: International Medicine & Public Health Source Type: news

ACRES and EXOCHAIN To Accelerate Clinical Research with LYNK...
The Alliance for Clinical Research Excellence and Safety® signs Agreement with EXOCHAIN™ to Provide Blockchain Technology in Support of Patient and Physician Secure Identity in Clinical Trials.(PRWeb January 17, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15097398.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 17, 2018 Category: Pharmaceuticals Source Type: news

J & J ’ s Biosense Webster launches WaveCrest study
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster said today that the first patient has been enrolled in an investigational device exemption trial for its WaveCrest system. The 1,250-patient study is designed to assess the safety and efficacy of the WaveCrest left atrial appendage occlusion system as a way to reduce the risk of embolic stroke in atrial fibrillation patients. “The WaveCrest System is designed to enable physicians to close the heart’s LAA, where most stroke-causing blood clots occur,” Dr. Larry Chinitz, who treated the first patient in the trial at New York University...
Source: Mass Device - January 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials BioSense Webster Inc. johnsonandjohnson Source Type: news

WaveForm touts clinical trial data for continuous glucose monitor
WaveForm Technologies said today that it has finished four clinical trials of its continuous glucose monitoring system and that it expects to win CE Mark clearance for the device this year. The WaveForm CGM system is designed to be worn for 14 days and includes a sensor insertion tool, a small sensor wire, a polymer coating and an on-body transmitter. Get the full story at our sister site, Drug Delivery Business News. The post WaveForm touts clinical trial data for continuous glucose monitor appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Pharmaceuticals Research & Development Dexcom waveformtechnologies Source Type: news

Cells to Society: New Hypertension Guidelines / Caregiver-Researcher/ Research News
This study investigates whether improved communication and evidence-based recommendations for handover yield positive patient outcomes.     Read more   Family ...
Source: Johns Hopkins University and Health Systems Archive - January 16, 2018 Category: Nursing Source Type: news

Secant Group officials think they ’ ve cracked vascular regeneration: Here ’ s how
Secant Group today announced what it described as game-changing technology to advance vascular regeneration, solving problems that surgeons presently have when it comes to vascular harvesting and the non-resorbable synthetic graft compliance mismatching. The technology, which Secant (Telford, Pa.) developed in partnership with its sister company SanaVita Medical, involves a synthetic, small bore, vessel with a hollow lumen construct infused with Secant’s proprietary Regenerez bioresorbable polymer technology. Early pre-clinical studies have shown the Regenerez grafts to be non-thrombogenic; they did not sho...
Source: Mass Device - January 16, 2018 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News Cardiovascular News Well Regenerative Medicine Research & Development Secant Group Source Type: news

FDA to release more clinical trial information for newly approved drugs
The Food and Drug Administration is taking steps to make it easier for doctors, patients and researchers to get access to clinical trial data amassed during the process of approving new drugs, Commissioner Scott Gottlieb said Tuesday. Gottlieb announced the actions just before a speech on FDA transparency at a Washington forum. The meeting, attended by […]Related:CDC postpones session on ‘preparing for the unthinkable’: a nuclear blastFirst treatment approved for breast cancer with BRCA genetic mutationCDC says, ‘There’s lots of flu in lots of places.’ And it’s not going away...
Source: Washington Post: To Your Health - January 16, 2018 Category: Consumer Health News Source Type: news

New treatment for SMA offers hope for Arianna
For the first few months of Arianna Condon’s life, everything was moving along fine. She was a happy baby, and seemed to be developing much like her older sister, Tessa. “She was gaining weight, and seemed to be doing great,” says Arianna’s mom, Marina. “She did have problems with reflux, but it was nothing too unusual for a baby.” But by the time Arianna was 3 months old, Marina started to have concerns. Arianna wasn’t lifting her head the way Tessa had at that age. Something didn’t seem right. “I brought it up to her pediatrician, but she told me that all babies devel...
Source: Thrive, Children's Hospital Boston - January 16, 2018 Category: Pediatrics Authors: Ellen Greenlaw Tags: Diseases & Conditions Our Patients’ Stories Dr. Basil Darras spinal muscular atrophy spinal muscular atrophy program Spinraza Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs
SILVER SPRING, Md., Jan. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Scientific progress and new drug innovation don't take place in a vacuum. The exchange of information that informs decisions to undertake research, invest in new scientific ende... Biopharmaceuticals, FDA clinical trials (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Fluids May Buy Dying Cancer Patients a Day or Two
TUESDAY, Jan. 16, 2018 -- Giving fluids to dying cancer patients may help them live a bit longer, a new British study finds. " Hydration plays a key role in delaying the dying process, " said Dr. Agnieszka Michael, medical director of clinical trials... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 16, 2018 Category: General Medicine Source Type: news

Abbott, Nevro tout spinal cord stimulation tech
Abbott (NYSE:ABT) and Nevro (NYSE:NVRO) touted their spinal cord stimulation technologies at the annual North American Neurological Society meeting in Las Vegas. Two-year data from Abbott’s 42-patient Sunburst study revealed that a majority of patients chose its BurstDR therapy when given the choice during the long-term follow-up period and that stimulation from BurstDR provided pain relief through 24 months. Patient preference for Abbott’s BurstDR system grew over time, the company pointed out – 68% of patients chose BurstDR at 12 months compared to 81% at two years. “The BurstDR waveform is b...
Source: Mass Device - January 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neurological Neuromodulation/Neurostimulation Pain Management Wall Street Beat Abbott nevro Source Type: news

FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs
FDA takes steps to enhance transparency of clinical trial data used in support of new drug approvals (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 16, 2018 Category: American Health Source Type: news

RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials Partner/Out-license robust dermatology and ophthalmology franchises to strengthen the Company's balan... Biopharmaceuticals, Oncology RXi Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Researchers identify new way to unmask melanoma cells to the immune system
(Duke University Medical Center) A research team at the Duke Cancer Institute has found a new way to keep the immune system engaged, and is planning to test the approach in a phase 1 clinical trial. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 16, 2018 Category: Biology Source Type: news

WCG Announces — Strategies that Inform Investigation Selection and...
Clinical trial operators have no choice but to contract with sites. But are they optimizing the opportunity to accelerate study start-up, reduce expenses, and avoid complications?(PRWeb January 16, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15088116.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 16, 2018 Category: Pharmaceuticals Source Type: news

Google venture arm backs universal flu vaccine clinical trial
A U.K. company developing what it hopes will be a universal flu vaccine has raised $27 million US from investors including GV, the venture capital arm of Google parent Alphabet Inc. (Source: CBC | Health)
Source: CBC | Health - January 15, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44 Clinical Trial Optional)
This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. (Source: HSR Information Central)
Source: HSR Information Central - January 15, 2018 Category: International Medicine & Public Health Source Type: news

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42 - Clinical Trial Optional)
This FOA encourages STTR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard STTR guidelines. (Source: HSR Information Central)
Source: HSR Information Central - January 15, 2018 Category: International Medicine & Public Health Source Type: news

Digital Science launches Dimensions: next-generation research and discovery platform
Ground-breaking research information database links publications, grants, policy, data and metrics for the first time Global technology company Digital Science is proud to announce the launch of Dimensions, a new platform that aims to democratise and transform scholarly search. A collaboration between six Digital Science portfolio companies (Altmetric, Digital Science Consultancy, Figshare, Readcube, Symplectic and ÜberResearch) and more than 100 research funders and universities, Dimensions offers a better, faster way to discover, understand and analyse the global research landscape, without wasting time searching fo...
Source: News from STM - January 15, 2018 Category: Databases & Libraries Authors: STM Publishing News Tags: Digital Featured Source Type: news

Promising Experimental Drug Treating Dogs With Cancer
NORTH GRAFTON (CBS) – When it comes to cancer research, dogs just might be the key to unlock vital clues needed to find a cure. Veterinarians in central Massachusetts are excited about some recent results and it’s also making for some extremely thankful pet owners. “They gave me my best friend back and they gave him more time, quality time,” said Edward Sloan, whose dog, Dozer, a 7-year-old bull mastiff, became sick last fall. “All of sudden he went blind, overnight,” Sloan said. “He was scared.  He was sad.” Dozer had cancer. Dozer, a 7-year-old bull mastiff, is be...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 13, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Cancer Dr. Mallika Marshall Source Type: news

Boston Scientific touts spinal cord stim pain-relief trial
This study provides data on people who have suffered with chronic pain for years and who pose some of the biggest challenges in the long-term use of SCS. The results demonstrated that giving patients the choice to use sub-perception or paresthesia-based therapy provides superior patient outcomes and affirms that SCS is a clinically valuable treatment option.” The trial showed that if patients are able to choose the type of therapy that brings them the most effective pain relief, the number of people whose pain was effectively controlled by SCS jumped by 62%. More than half of the patients in one of the study’s ...
Source: Mass Device - January 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neuromodulation/Neurostimulation Pain Management Spinal Wall Street Beat Boston Scientific Source Type: news

Immunotherapy highly effective in treatment of rare skin cancer, study finds
FINDINGSIn a UCLA-led study, more than two-thirds of people with a rare type of melanoma responded positively to treatment with anti-PD-1 immunotherapies. The findings, which counter the conventional wisdom that a cancer which is highly fibrotic could not respond to immunotherapy, have the potential to help scientists identify those patients most likely to benefit from treatment.BACKGROUNDDesmoplastic melanoma is an uncommon subtype of melanoma that has proven highly resistant to traditional treatment approaches, such as chemotherapy, radiation and surgery. Desmoplastic melanoma tumors have a very dense tissue thought to l...
Source: UCLA Newsroom: Health Sciences - January 12, 2018 Category: Universities & Medical Training Source Type: news

Precision Medicine Requires Targeted Cancer Therapies, but Payers Reluctant to Pay for Some Genetic Testing Needed to Match a Patient with Right Drug
Clinical labs and pathology groups know how advances in targeted therapies and genomics far outpace providers’ and patients’ ability to know how best to use and pay for them One fascinating development on the road to precision medicine is that many new cancer drugs now in clinical trials will require a companion genetic test to […] (Source: Dark Daily)
Source: Dark Daily - January 12, 2018 Category: Laboratory Medicine Authors: Jude Tags: Coding, Billing, and Collections Compliance, Legal, and Malpractice Instruments & Equipment Laboratory News Laboratory Operations Laboratory Pathology Laboratory Testing Management & Operations anatomic pathology and Cancer Genetics BR Source Type: news